Oxidative damage to macromolecules in human Parkinson disease and the rotenone model

Free Radical Biology and Medicine

Volumn 62, Issue , 2013, Pages 111-120

  Sanders, Laurie H ^a   Greenamyren, J Timothy ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Free radicals; Macromolecules; Oxidative damage; Parkinson disease; Rotenone

Indexed keywords

BRAIN PROTEIN; LIPID; MITOCHONDRIAL DNA; NUCLEIC ACID; ROTENONE;

ANIMAL MODEL; CENTRAL NERVOUS SYSTEM; DNA DAMAGE; DNA REPAIR; DOPAMINERGIC NERVE CELL; HUMAN; LIPID BRAIN LEVEL; LIPID PEROXIDATION; MACROMOLECULE; NERVE DEGENERATION; NEUROPATHOLOGY; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

ANIMALIA;

EID: 84884902071     PISSN: 08915849     EISSN: 18734596     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2013.01.003     Document Type: Review

References (183)

1. Halliwell, B. Phagocyte-derived reactive species: salvation or suicide? Trends Biochem. Sci 31: 509-515; 2006. (Pubitemid 44279983)
2. Halliwell, B. Chloroplast Metabolism. London: Oxford Univ. Press; 1984.
3. Halestrap, A. Biochemistry: a pore way to die. Nature 434: 578-579; 2005. (Pubitemid 40488541)
4. Babcock, G. T. How oxygen is activated and reduced in respiration. Proc. Natl. Acad. Sci. USA 96: 12971-12973; 1999.
5. St-Pierre, J., et al. Topology of superoxide production from different sites in the mitochondrial electron transport chain. J. Biol. Chem 277: 44784-44790; 2002. (Pubitemid 36159072)
6. Halliwell, B.; Gutteridge, J. Free Radicals in Biology and Medicine. 4th edition London: Oxford Univ. Press; 2007.
7. Harman, D. Aging: a theory based on free radical and radiation chemistry. J. Gerontol. 11: 298-300; 1956.
8. Horowitz, M. P.; Greenamyre, J. T. Gene-environment interactions in Parkinson's disease: the importance of animal modeling. Clin. Pharmacol. Ther. 88: 467-474; 2010.
9. Haigis, M.C., Yankner, B.A., The aging stress response. Mol. Cell 40: 333-344.
10. Trachootham, D.; Alexandre, J.; Huang, P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat. Rev. Drug Discovery 8: 579-591; 2009.
11. Shukla, V.; Mishra, S. K.; Pant, H. C. Oxidative stress in neurodegeneration. Adv. Pharmacol. Sci. 2011: 572634; 2011.
12. Martinez, T. N.; Greenamyre, J. T. Toxin models of mitochondrial dysfunction in Parkinson's disease. Antioxid. Redox Signaling 16: 920-934; 2012.
13. Hely, M. A., et al. The Sydney Multicentre Study of Parkinson's disease: a report on the first 3 years. J. Neurol. Neurosurg. Psychiatry 52: 324-328; 1989. (Pubitemid 19075075)
14. Levy, G., et al. The association of incident dementia with mortality in PD. Neurology 59: 1708-1713; 2002. (Pubitemid 35424451)
15. Morgante, L., et al. Parkinson disease survival: a population-based study. Arch. Neurol. 57: 507-512; 2000. (Pubitemid 30212124)
16. Forno, L. S. Neuropathology of Parkinson's disease. J. Neuropathol. Exp. Neurol. 55: 259-272; 1996. (Pubitemid 26085575)
17. Spillantini, M. G., et al. alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc. Natl. Acad. Sci. USA 95: 6469-6473; 1998. (Pubitemid 28249037)
18. Jellinger, K. A. Formation and development of Lewy pathology: a critical update. J. Neurol 256(Suppl. 3): 270-279; 2009.
19. Hornykiewicz, O.; Kish, S. J. Biochemical pathophysiology of Parkinson's disease. Adv. Neurol. 45: 19-34; 1987.
20. Mariani, E., et al. Oxidative stress in brain aging, neurodegenerative and vascular diseases: an overview. J. Chromatogr. B. Anal. Technol. Biomed. Life Sci. 827: 65-75; 2005. (Pubitemid 41551598)
21. Evans, M. D.; Dizdaroglu, M.; Cooke, M. S. Oxidative DNA damage and disease: induction, repair and significance. Mutat. Res. 567: 1-61; 2004. (Pubitemid 39162992)
22. Nunomura, A., et al. Oxidative damage to RNA in aging and neurodegen-erative disorders. Neurotox. Res. 22: 231-248; 2012.
23. Alam, Z. I., et al. Oxidative DNA damage in the parkinsonian brain: an apparent selective increase in 8-hydroxyguanine levels in substantia nigra. J. Neurochem 69: 1196-1203; 1997. (Pubitemid 27364841)
24. Zhang, J., et al. Parkinson's disease is associated with oxidative damage to cytoplasmic DNA and RNA in substantia nigra neurons. Am. J. Pathol 154: 1423-1429; 1999. (Pubitemid 29226437)
25. Hegde, M. L., et al. Studies on genomic DNA topology and stability in brain regions of Parkinson's disease. Arch. Biochem. Biophys 449: 143-156; 2006.
26. Maynard, S., et al. Mitochondrial base excision repair assays. Methods 51: 416-425; 2010.
27. Richter, C.; Park, J. W.; Ames, B. N. Normal oxidative damage to mitochon-drial and nuclear DNA is extensive. Proc. Natl. Acad. Sci. USA 85: 6465-6467; 1988.
28. Mecocci, P., et al. Oxidative damage to mitochondrial DNA shows marked age-dependent increases in human brain. Ann. Neurol 34: 609-616; 1993. (Pubitemid 23289414)
29. Slupphaug, G.; Kavli, B.; Krokan, H. E. The interacting pathways for prevention and repair of oxidative DNA damage. Mutat. Res. 531: 231-251; 2003. (Pubitemid 37456735)
30. Michaels, M. L.; Miller, J. H. The GO system protects organisms from the mutagenic effect of the spontaneous lesion 8-hydroxyguanine (7,8-dihydro-8- oxoguanine). J. Bacteriol 174: 6321-6325; 1992.
31. Tornaletti, S. DNA repair in mammalian cells: transcription-coupled DNA repair: directing your effort where it's most needed. Cell. Mol. Life Sci 66: 1010-1020; 2009.
32. Kikuchi, A., et al. Systemic increase of oxidative nucleic acid damage in Parkinson's disease and multiple system atrophy. Neurobiol. Dis 9: 244-248; 2002. (Pubitemid 34261218)
33. Abe, T., et al. Alteration of 8-hydroxyguanosine concentrations in the cerebrospinal fluid and serum from patients with Parkinson's disease. Neurosci. Lett 336: 105-108; 2003. (Pubitemid 36009318)
34. Oli, R. G., et al. No increased chromosomal damage in L-DOPA-treated patients with Parkinson's disease: a pilot study. J. Neural Transm 117: 737-746; 2010.
35. Cornetta, T., et al. Levodopa therapy reduces DNA damage in peripheral blood cells of patients with Parkinson's disease. Cell. Biol. Toxicol 25: 321-330; 2009.
36. Migliore, L., et al. Oxidative damage and cytogenetic analysis in leukocytes of Parkinson's disease patients. Neurology 58: 1809-1815; 2002. (Pubitemid 34663582)
37. Migliore, L., et al. Chromosome and oxidative damage biomarkers in lymphocytes of Parkinson's disease patients. Int. J. Hyg. Environ. Health 204: 61-66; 2001. (Pubitemid 33031902)
38. Petrozzi, L., et al. Cytogenetic analysis oxidative damage in lymphocytes of Parkinson's disease patients. Neurol. Sci 22: 83-84; 2001. (Pubitemid 33622093)
39. Seet, R. C., et al. Oxidative damage in Parkinson disease: measurement using accurate biomarkers. Free Radic. Biol. Med. 48: 560-566; 2010.
40. Sato, S.; Mizuno, Y.; Hattori, N. Urinary 8-hydroxydeoxyguanosine levels as a biomarker for progression of Parkinson disease. Neurology 64: 1081-1083; 2005. (Pubitemid 40388471)
41. Friedberg, E.C., Walker, G.C., Siede, W., Wood, R.D., Schultz, R.A., Ellenberger, T., DNA Repair and Mutagenesis, 2nd ed. Washington, DC: Am. Soc. Microbiol.; 2006.
42. Shimura-Miura, H., et al. Increased 8-oxo-dGTPase in the mitochondria of substantia nigral neurons in Parkinson's disease. Ann. Neurol 46: 920-924; 1999.
43. Arai, T., et al. Up-regulation of hMUTYH, a DNA repair enzyme, in the mitochondria of substantia nigra in Parkinson's disease. Acta Neuropathol 112: 139-145; 2006.
44. Fukae, J., et al. Expression of 8-oxoguanine DNA glycosylase (OGG1) in Parkinson's disease and related neurodegenerative disorders. Acta Neuro-pathol 109: 256-262; 2005. (Pubitemid 41166594)
45. Gencer, M., et al. DNA repair genes in Parkinson's disease. Genet. Test. Mol. Biomarkers 16: 504-507; 2012.
46. Elstner, M., et al. Neuromelanin, neurotransmitter status and brainstem location determine the differential vulnerability of catecholaminergic neurons to mitochondrial DNA deletions. Mol. Brain 4: 43; 2011.
47. Bender, A., et al. High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease. Nat. Genet 38: 515-517; 2006.
48. Kraytsberg, Y., et al. Mitochondrial DNA deletions are abundant and cause functional impairment in aged human substantia nigra neurons. Nat. Genet 38: 518-520; 2006.
49. Lin, M. T., et al. Somatic mitochondrial DNA mutations in early Parkinson and incidental Lewy body disease. Ann. Neurol 71: 850-854; 2012.
50. Vermulst, M.; Wanagat, J.; Loeb, L. A. On mitochondria, mutations, and methodology. Cell Metab. 10: 437; 2009.
51. Chen, C. T., et al. Regulation of brain polyunsaturated fatty acid uptake and turnover. Prostaglandins Leukotrienes Essent. Fatty Acids 79: 85-91; 2008.
52. Svennerholm, L. Distribution and fatty acid composition of phosphoglycer-ides in normal human brain. J. Lipid Res 9: 570-579; 1968.
53. Ruiperez, V.; Darios, F.; Davletov, B. Alpha-synuclein, lipids and Parkinson's disease. Prog. Lipid Res. 49: 420-428; 2010.
54. Bochkov, V. N., et al. Protective role of phospholipid oxidation products in endotoxin-induced tissue damage. Nature 419: 77-81; 2002. (Pubitemid 34987873)
55. Roberts 2nd L. J.; Fessel, J. P. The biochemistry of the isoprostane, neuroprostane, and isofuran pathways of lipid peroxidation. Chem. Phys. Lipids 128: 173-186; 2004. (Pubitemid 38167386)
56. Ross, B. M., et al. Low activity of key phospholipid catabolic and anabolic enzymes in human substantia nigra: possible implications for Parkinson's disease. Neuroscience 83: 791-798; 1998. (Pubitemid 28068899)
57. Dexter, D. T., et al. Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J. Neurochem 52: 381-389; 1989. (Pubitemid 19037600)
58. Mythri, R. B., et al. Evaluation of markers of oxidative stress, antioxidant function and astrocytic proliferation in the striatum and frontal cortex of Parkinson's disease brains. Neurochem. Res 36: 1452-1463; 2011.
59. Navarro, A., et al. Human brain cortex: mitochondrial oxidative damage and adaptive response in Parkinson disease and in dementia with Lewy bodies. Free Radic. Biol. Med 46: 1574-1580; 2009.
60. Dexter, D. T., et al. Increased levels of lipid hydroperoxides in the parkinsonian substantia nigra: an HPLC and ESR study. Mov. Disord 9: 92-97; 1994. (Pubitemid 24022621)
61. Fessel, J. P., et al. Isofurans, but not F2-isoprostanes, are increased in the substantia nigra of patients with Parkinson's disease and with dementia with Lewy body disease. J. Neurochem 85: 645-650; 2003. (Pubitemid 36531927)
62. Shamoto-Nagai, M., et al. In parkinsonian substantia nigra, alpha-synuclein is modified by acrolein, a lipid-peroxidation product, and accumulates in the dopamine neurons with inhibition of proteasome activity. J. Neural Transm 114: 1559-1567; 2007. (Pubitemid 350212012)
63. Castellani, R. J., et al. Hydroxynonenal adducts indicate a role for lipid peroxidation in neocortical and brainstem Lewy bodies in humans. Neurosci. Lett 319: 25-28; 2002. (Pubitemid 34117635)
64. Yoritaka, A., et al. Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. Proc. Natl. Acad. Sci. USA 93: 2696-2701; 1996. (Pubitemid 26114311)
65. Pratico, D., et al. Increased F2-isoprostanes in Alzheimer's disease: evidence for enhanced lipid peroxidation in vivo. FASEB J. 12: 1777-1783; 1998. (Pubitemid 28553673)
66. Sanyal, J., et al. Plasma levels of lipid peroxides in patients with Parkinson's disease. Eur. Rev. Med. Pharmacol. Sci. 13: 129-132; 2009.
67. Lee, C. Y., et al. Different patterns of oxidized lipid products in plasma and urine of dengue fever, stroke, and Parkinson's disease patients: cautions in the use of biomarkers of oxidative stress. Antioxid. Redox Signaling 11: 407-420; 2009.
68. Kalra, J., et al. Oxygen free radical producing activity of polymorphonuclear leukocytes in patients with Parkinson's disease. Mol. Cell. Biochem 112: 181-186; 1992.
69. Molina, J. A., et al. Serum lipid peroxides in patients with Parkinson's disease. Neurosci. Lett. 136: 137-140; 1992.
70. Ahlskog, J. E., et al. No evidence for systemic oxidant stress in Parkinson's or Alzheimer's disease. Mov. Disord 10: 566-573; 1995.
71. Cristalli, D. O., et al. Peripheral markers in neurodegenerative patients and their first-degree relatives. J. Neurol. Sci. 314: 48-56; 2012.
72. Kilinc, A., et al. Increased erythrocyte susceptibility to lipid peroxidation in human Parkinson's disease. Neurosci. Lett 87: 307-310; 1988.
73. Agil, A., et al. Plasma lipid peroxidation in sporadic Parkinson's disease: role of the L-dopa. J. Neurol. Sci. 240: 31-36; 2006. (Pubitemid 41814950)
74. Connolly, J., et al. F2 isoprostane levels in plasma and urine do not support increased lipid peroxidation in cognitively impaired Parkinson disease patients. Cognit. Behav. Neurol 21: 83-86; 2008.
75. Irizarry, M. C., et al. Plasma F2A isoprostane levels in Alzheimer's and Parkinson's disease. Neurodegener. Dis 4: 403-405; 2007. (Pubitemid 47557280)
76. Boll, M. C., et al. Free copper, ferroxidase and SOD1 activities, lipid peroxidation and NO(x) content in the CSF: a different marker profile in four neurodegen-erative diseases. Neurochem. Res 33: 1717-1723; 2008.
77. Selley, M. L. (E)-4-Hydroxy-2-nonenal may be involved in the pathogenesis of Parkinson's disease. Free Radic. Biol. Med 25: 169-174; 1998. (Pubitemid 28293150)
78. Ilic, T. V., et al. Oxidative stress indicators are elevated in de novo Parkinson's disease patients. Funct. Neurol 14: 141-147; 1999.
79. Shukla, R., et al. Nitrite and malondialdehyde content in cerebrospinal fluid of patients with Parkinson's disease. Int. J. Neurosci 116: 1391-1402; 2006. (Pubitemid 44915013)
80. Musanti, R., et al. Decreased cholesterol biosynthesis in fibroblasts from patients with Parkinson disease. Biochem. Med. Metab. Biol. 49: 133-142; 1993. (Pubitemid 23197786)
81. Hoepken, H. H., et al. Mitochondrial dysfunction, peroxidation damage and changes in glutathione metabolism in PARK6. Neurobiol. Dis. 25: 401-411; 2007.
82. Cooper, O.; Hallett, P.; Isacson, O. Using stem cells and iPS cells to discover new treatments for Parkinson's disease. Parkinsonism Relat. Disord 18(Suppl. 1):S14-16; 2012.
83. Paradies, G., et al. Age-dependent decline in the cytochrome c oxidase activity in rat heart mitochondria: role of cardiolipin. FEBS Lett 406: 136-138; 1997. (Pubitemid 27156975)
84. Pope, S.; Land, J. M.; Heales, S. J. Oxidative stress and mitochondrial dysfunction in neurodegeneration: cardiolipin a critical target? Biochim. Biophys. Acta 1777: 794-799; 2008.
85. Bayir, H., et al. Peroxidase mechanism of lipid-dependent cross-linking of synuclein with cytochrome C: protection against apoptosis versus delayed oxidative stress in Parkinson disease. J. Biol. Chem 284: 15951-15969; 2009.
86. Almeida Mdo, R., Glucocerebrosidase involvement in Parkinson disease and other synucleinopathies. Front. Neurol. 3: 65.
87. Alam, Z. I., et al. A generalised increase in protein carbonyls in the brain in Parkinson's but not incidental Lewy body disease. J. Neurochem 69: 1326-1329; 1997. (Pubitemid 27364859)
88. Keeney, P. M., et al. Parkinson's disease brain mitochondrial complex I has oxidatively damaged subunits and is functionally impaired and misas-sembled. J. Neurosci 26: 5256-5264; 2006. (Pubitemid 44315308)
89. Bonifati, V., et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 299: 256-259; 2003. (Pubitemid 36131051)
90. Bandopadhyay, R., et al. The expression of DJ-1 (PARK7) in normal human CNS and idiopathic Parkinson's disease. Brain 127: 420-430; 2004. (Pubitemid 38160326)
91. Blackinton, J., et al. Post-transcriptional regulation of mRNA associated with DJ-1 in sporadic Parkinson disease. Neurosci. Lett 452: 8-11; 2009.
92. Choi, J., et al. Oxidative damage of DJ-1 is linked to sporadic Parkinson and Alzheimer diseases. J. Biol. Chem 281: 10816-10824; 2006. (Pubitemid 43855504)
93. Kitada, T., et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392: 605-608; 1998. (Pubitemid 28207717)
94. Choi, J., et al. Oxidative modifications and down-regulation of ubiquitin carboxyl-terminal hydrolase L1 associated with idiopathic Parkinson's and Alzheimer's diseases. J. Biol. Chem 279: 13256-13264; 2004. (Pubitemid 38445905)
95. Horowitz, M.P., Greenamyre, J.T. Mitochondrial iron metabolism and its role in neurodegeneration. J. Alzheimers Dis. 20(Suppl. 2):S551-S568.
96. Mastroberardino, P. G., et al. A novel transferrin/TfR2-mediated mitochon-drial iron transport system is disrupted in Parkinson's disease. Neurobiol. Dis 34: 417-431; 2009.
97. Watfa, G., et al. Study of telomere length and different markers of oxidative stress in patients with Parkinson's disease. J. Nutr. Health Aging 15: 277-281; 2011.
98. Baillet, A., et al. The role of oxidative stress in amyotrophic lateral sclerosis and Parkinson's disease. Neurochem. Res 35: 1530-1537; 2010.
99. Saito, Y., et al. Preparation and application of monoclonal antibodies against oxidized DJ-1: significant elevation of oxidized DJ-1 in erythrocytes of early-stage Parkinson disease patients. Neurosci. Lett 465: 1-5; 2009.
100. Tanner, C. M., et al. Parkinson disease in twins: an etiologic study. JAMA 281: 341-346; 1999. (Pubitemid 29061038)
101. Wirdefeldt, K., et al. Complete ascertainment of Parkinson disease in the Swedish Twin Registry. Neurobiol. Aging 29: 1765-1773; 2008.
102. Wirdefeldt, K., et al. No evidence for heritability of Parkinson disease in Swedish twins. Neurology 63: 305-311; 2004. (Pubitemid 38971131)
103. Lin, M. T.; Simon, D. K. No evidence for heritability of Parkinson disease in Swedish twins. Neurology 64: 932; 2005. author reply 932. (Pubitemid 40316353)
104. Kosel, S., et al. Parkinson disease: analysis of mitochondrial DNA in monozygotic twins. Neurogenetics 2: 227-230; 2000. (Pubitemid 30196001)
105. Vieregge, P., et al. Parkinson's disease in twins. Neurology 42: 1453-1461; 1992.
106. Rosati, G., et al. The risk of Parkinson disease in Mediterranean people. Neurology 30: 250-255; 1980. (Pubitemid 10133759)
107. Zhang, Z. X.; Roman, G. C. Worldwide occurrence of Parkinson's disease: an updated review. Neuroepidemiology 12: 195-208; 1993. (Pubitemid 23353338)
108. Twelves, D.; Perkins, K. S.; Counsell, C. Systematic review of incidence studies of Parkinson's disease. Mov. Disord 18: 19-31; 2003. (Pubitemid 36150204)
109. Ashok, P. P., et al. Epidemiology of Parkinson's disease in Benghazi, NorthEast Libya. Clin. Neurol. Neurosurg. 88: 109-113; 1986. (Pubitemid 16047274)
110. Cannon, J.R., Greenamyre, J.T. Gene-environment interactions in Parkinson's disease: specific evidence in humans and mammalian models. Neurobiol. Dis., in press.
111. Tanner, C. M., et al. Smoking and Parkinson's disease in twins. Neurology 58: 581-588; 2002. (Pubitemid 34164940)
112. Wirdefeldt, K., et al. Risk and protective factors for Parkinson's disease: a study in Swedish twins. Ann. Neurol 57: 27-33; 2005. (Pubitemid 40053312)
113. Hertzman, C., et al. Parkinson's disease: a case-control study of occupational and environmental risk factors. Am. J. Ind. Med. 17: 349-355; 1990.
114. Gorell, J. M., et al. The risk of Parkinson's disease with exposure to pesticides, farming, well water, and rural living. Neurology 50: 1346-1350; 1998. (Pubitemid 28240350)
115. Hubble, J. P., et al. Risk factors for Parkinson's disease. Neurology 43: 1693-1697; 1993. (Pubitemid 23307937)
116. Hernan, M. A., et al. A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease. Ann. Neurol. 52: 276-284; 2002. (Pubitemid 35001493)
117. Liou, H. H., et al. Environmental risk factors and Parkinson's disease: a case- control study in Taiwan. Neurology 48: 1583-1588; 1997.
118. Stephenson, J. Exposure to home pesticides linked to Parkinson disease. JAMA 283: 3055-3056; 2000. (Pubitemid 30399702)
119. Tanner, C. M.; Goldman, S. M. Epidemiology of Parkinson's disease. Neurol. Clin. 14: 317-335; 1996. (Pubitemid 26157425)
120. Gorell, J. M., et al. Occupational exposure to manganese, copper, lead, iron, mercury and zinc and the risk of Parkinson's disease. Neurotoxicology 20: 239-247; 1999.
121. Gorell, J. M., et al. Occupational metal exposures and the risk of Parkinson's disease. Neuroepidemiology 18: 303-308; 1999. (Pubitemid 29493517)
122. Racette, B. A., et al. Welding-related parkinsonism: clinical features, treatment, and pathophysiology. Neurology 56: 8-13; 2001.
123. Galvani, P.; Fumagalli, P.; Santagostino, A. Vulnerability of mitochondrial complex I in PC12 cells exposed to manganese. Eur. J. Pharmacol. 293: 377-383; 1995. (Pubitemid 3006675)
124. Gavin, C. E.; Gunter, K. K.; Gunter, T. E. Manganese and calcium transport in mitochondria: implications for manganese toxicity. Neurotoxicology 20: 445-453; 1999.
125. Hatcher, J. M.; Pennell, K. D.; Miller, G. W. Parkinson's disease and pesticides: a toxicological perspective. Trends Pharmacol. Sci. 29: 322-329; 2008.
126. Dick, F. D. Parkinson's disease and pesticide exposures. Br. Med. Bull. 79-80: 219-231; 2006.
127. Semchuk, K. M.; Love, E. J.; Lee, R. G. Parkinson's disease and exposure to agricultural work and pesticide chemicals. Neurology 42: 1328-1335; 1992.
128. Kamel, F., et al. Pesticide exposure and self-reported Parkinson's disease in the agricultural health study. Am. J. Epidemiol 165: 364-374; 2007.
129. Tanner, C. M. Epidemiology of Parkinson's disease. Neurol. Clin. 10: 317-329; 1992.
130. Greenamyre, J. T., et al. Complex I and Parkinson's disease. IUBMB Life 52: 135-141; 2001. (Pubitemid 33731566)
131. Lummen, P. Complex I inhibitors as insecticides and acaricides. Biochim. Biophys. Acta 1364: 287-296; 1998. (Pubitemid 28291846)
132. Betarbet, R., et al. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat. Neurosci 3: 1301-1306; 2000.
133. Cannon, J. R., et al. A highly reproducible rotenone model of Parkinson's disease. Neurobiol. Dis. 34: 279-290; 2009.
134. Hancock, D. B., et al. Pesticide exposure and risk of Parkinson's disease: a family-based case-control study. BMC Neurol 8: 6; 2008.
135. Dhillon, A. S., et al. Pesticide/environmental exposures and Parkinson's disease in East Texas. J. Agromed 13: 37-48; 2008.
136. Tanner, C. M., et al. Rotenone, paraquat, and Parkinson's disease. Environ. Health Perspect. 119: 866-872; 2011.
137. Talpade, D. J., et al. In vivo labeling of mitochondrial complex I (NADH: ubiquinone oxidoreductase) in rat brain using [3H]dihydrorotenone. J. Neurochem 75: 2611-2621; 2000.
138. Heikkila, R. E., et al. Dopaminergic toxicity of rotenone and the 1-methyl-4-phenylpyridinium ion after their stereotaxic administration to rats: implication for the mechanism of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity. Neurosci. Lett 62: 389-394; 1985. (Pubitemid 16147750)
139. Ferrante, R. J., et al. Systemic administration of rotenone produces selective damage in the striatum and globus pallidus, but not in the substantia nigra. Brain Res 753: 157-162; 1997. (Pubitemid 27156146)
140. Higgins Jr. D. S.; Greenamyre, J. T. [3H]Dihydrorotenone binding to NADH: ubiquinone reductase (complex I) of the electron transport chain: an autoradiographic study. J. Neurosci. 16: 3807-3816; 1996. (Pubitemid 26176045)
141. Sherer, T. B., et al. An in vitro model of Parkinson's disease: linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage. J. Neurosci 22: 7006-7015; 2002. (Pubitemid 35379158)
142. Betarbet, R., et al. Intersecting pathways to neurodegeneration in Parkinson's disease: effects of the pesticide rotenone on DJ-1, alpha-synuclein, and the ubiquitin-proteasome system. Neurobiol. Dis 22: 404-420; 2006. (Pubitemid 44294281)
143. Wang, X. F., et al. Inhibitory effects of pesticides on proteasome activity: implication in Parkinson's disease. Neurobiol. Dis. 23: 198-205; 2006.
144. Drolet, R. E., et al. Chronic rotenone exposure reproduces Parkinson's disease gastrointestinal neuropathology. Neurobiol. Dis. 36: 96-102; 2009.
145. Greene, J. G.; Noorian, A. R.; Srinivasan, S. Delayed gastric emptying and enteric nervous system dysfunction in the rotenone model of Parkinson's disease. Exp. Neurol. 218: 154-161; 2009.
146. Sindhu, K. M., et al. Rats with unilateral median forebrain bundle, but not striatal or nigral, lesions by the neurotoxins MPP+ or rotenone display differential sensitivity to amphetamine and apomorphine. Pharmacol. Biochem. Behav 84: 321-329; 2006. (Pubitemid 44131477)
147. Alam, M.; Schmidt, W. J. L-DOPA reverses the hypokinetic behaviour and rigidity in rotenone-treated rats. Behav. Brain Res. 153: 439-446; 2004. (Pubitemid 38953119)
148. Rojas, J. C.; Saavedra, J. A.; Gonzalez-Lima, F. Neuroprotective effects of memantine in a mouse model of retinal degeneration induced by rotenone. Brain Res 1215: 208-217; 2008.
149. Biehlmaier, O.; Alam, M.; Schmidt, W. J. A rat model of Parkinsonism shows depletion of dopamine in the retina. Neurochem. Int. 50: 189-195; 2007. (Pubitemid 44879675)
150. Zhang, X.; Rojas, J. C.; Gonzalez-Lima, F. Methylene blue prevents neurode-generation caused by rotenone in the retina. Neurotox. Res. 9: 47-57; 2006.
151. Zhang, X.; Jones, D.; Gonzalez-Lima, F. Mouse model of optic neuropathy caused by mitochondrial complex I dysfunction. Neurosci. Lett. 326: 97-100; 2002. (Pubitemid 34607568)
152. Garcia-Garcia, F., et al. Sleep disturbances in the rotenone animal model of Parkinson disease. Brain Res 1042: 160-168; 2005. (Pubitemid 40591725)
153. Panov, A., et al. Rotenone model of Parkinson disease: multiple brain mitochondria dysfunctions after short term systemic rotenone intoxication. J. Biol. Chem 280: 42026-42035; 2005. (Pubitemid 43023171)
154. Feng, J. Microtubule: a common target for parkin and Parkinson's disease toxins. Neuroscientist 12: 469-476; 2006. (Pubitemid 44657962)
155. Jiang, Q.; Yan, Z.; Feng, J. Neurotrophic factors stabilize microtubules and protect against rotenone toxicity on dopaminergic neurons. J. Biol. Chem. 281: 29391-29400; 2006. (Pubitemid 44507082)
156. Ren, Y., et al. Selective vulnerability of dopaminergic neurons to microtubule depolymerization. J. Biol. Chem. 280: 34105-34112; 2005. (Pubitemid 41443134)
157. Choi, W. S., et al. Mitochondrial complex I inhibition is not required for dopaminergic neuron death induced by rotenone, MPP+, or paraquat. Proc. Natl. Acad. Sci. USA 105: 15136-15141; 2008.
158. Sherer, T. B., et al. Mechanism of toxicity in rotenone models of Parkinson's disease. J. Neurosci. 23: 10756-10764; 2003. (Pubitemid 37499681)
159. Marella, M., et al. Protection by the NDI1 gene against neurodegeneration in a rotenone rat model of Parkinson's disease. PLoS One 3:e1433; 2008.
160. Sterky, F. H., et al. Altered dopamine metabolism and increased vulnerability to MPTP in mice with partial deficiency of mitochondrial complex I in dopamine neurons. Hum. Mol. Genet 21: 1078-1089; 2012.
161. Seo, B. B., et al. The single subunit NADH dehydrogenase reduces generation of reactive oxygen species from complex I. FEBS Lett 580: 6105-6108; 2006. (Pubitemid 44666792)
162. Swarnkar, S., et al. Rotenone-induced apoptosis and role of calcium: a study on Neuro-2a cells. Arch. Toxicol 86: 1387-1397; 2012.
163. Jia, H., et al. Synergistic anti-parkinsonism activity of high doses of B vitamins in a chronic cellular model. Neurobiol. Aging 31: 636-646; 2010.
164. Porcelli, A. M., et al. Respiratory complex I dysfunction due to mitochondrial DNA mutations shifts the voltage threshold for opening of the permeability transition pore toward resting levels. J. Biol. Chem 284: 2045-2052; 2009.
165. de Lima, P. D., et al. Genotoxic effects of rotenone on cultured lymphocytes. Genet. Mol. Res. 4: 822-831; 2005.
166. Greene, J. G.; Greenamyre, J. T.; Dingledine, R. Sequential and concerted gene expression changes in a chronic in vitro model of parkinsonism. Neuroscience 152: 198-207; 2008.
167. Molina-Jimenez, M. F., et al. Neuroprotective effect of fraxetin and myricetin against rotenone-induced apoptosis in neuroblastoma cells. Brain Res 1009: 9-16; 2004. (Pubitemid 38553843)
168. Koopman, W. J., et al. Inhibition of complex I of the electron transport chain causes O^'-mediated mitochondrial outgrowth. Am. J. Physiol. Cell Physiol 288:C1440-1450; 2005. (Pubitemid 40991081)
169. Beretta, S., et al. Partial mitochondrial complex I inhibition induces oxidative damage and perturbs glutamate transport in primary retinal cultures: relevance to Leber hereditary optic neuropathy (LHON). Neurobiol. Dis 24: 308-317; 2006. (Pubitemid 44572749)
170. Sousa, S. C., et al. Ca2+-induced oxidative stress in brain mitochondria treated with the respiratory chain inhibitor rotenone. FEBS Lett 543: 179-183; 2003. (Pubitemid 36577251)
171. Swarnkar, S., et al., Rotenone induced neurotoxicity in rat brain areas: a histopathological study. Neurosci. Lett. 501: 123-127.
172. Verma, R.; Nehru, B. Effect of centrophenoxine against rotenone-induced oxidative stress in an animal model of Parkinson's disease. Neurochem. Int 55: 369-375; 2009.
173. Nehru, B., et al. Behavioral alterations in rotenone model of Parkinson's disease: attenuation by co-treatment of centrophenoxine. Brain Res 1201: 122-127; 2008.
174. Kaur, H., Chauhan, S., Sandhir, R., Protective effect of lycopene on oxidative stress and cognitive decline in rotenone induced model of Parkinson's disease. Neurochem. Res. 36: 1435-1443.
175. Sanchez-Reus, M. I., et al. Standardized Hypericum perforatum reduces oxidative stress and increases gene expression of antioxidant enzymes on rotenone-exposed rats. Neuropharmacology 52: 606-616; 2007. (Pubitemid 46123375)
176. Zaitone, S. A.; Abo-Elmatty, D. M.; Shaalan, A. A. Acetyl-L-carnitine and a-lipoic acid affect rotenone-induced damage in nigral dopaminergic neurons of rat brain, implication for Parkinson's disease therapy. Pharmacol. Biochem. Behav 100: 347-360; 2012.
177. Bashkatova, V., et al. Chronic administration of rotenone increases levels of nitric oxide and lipid peroxidation products in rat brain. Exp. Neurol 186: 235-241; 2004. (Pubitemid 38333196)
178. Kaneko, K., et al. Increased vulnerability to rotenone-induced neurotoxicity in ceruloplasmin-deficient mice. Neurosci. Lett 446: 56-58; 2008.
179. Hajieva, P., et al. Novel imine antioxidants at low nanomolar concentrations protect dopaminergic cells from oxidative neurotoxicity. J. Neurochem 110: 118-132; 2009.
180. Filomeni, G., et al. Neuroprotection of kaempferol by autophagy in models of rotenone-mediated acute toxicity: possible implications for Parkinson's disease. Neurobiol. Aging 33: 767-785; 2012.
181. Testa, C. M.; Sherer, T. B.; Greenamyre, J. T. Rotenone induces oxidative
182. Horowitz, M.P., et al., Single-cell redox imaging demonstrates a distinctive response of dopaminergic neurons to oxidative insults. Antioxid. Redox Signaling 15: 855-871.
183. Ramachandiran, S., et al. Divergent mechanisms of paraquat, MPP+, and rotenone toxicity: oxidation of thioredoxin and caspase-3 activation. Toxicol. Sci. 95: 163-171; 2007. 3) (Pubitemid 44970055)